Financial Performance - Full year net sales increased by 1.4% to $20,382 million, compared to $20,101 million in 2024[2] - GAAP EPS for the full year declined by 25% to $2.63, primarily due to impairment charges related to the skin health business[4] - Base Business EPS increased by 3% to $3.69 for the full year[2] - Fourth quarter net sales rose by 5.8% to $5,230 million, with organic sales growth of 2.2%[6] - GAAP EPS for the fourth quarter was $(0.05), a decline of 106% due to impairment charges[5] - For the full year 2025, net sales totaled $20,382 million, a slight increase from $20,101 million in 2024[32] - The company reported a net income of $2,132 million for the full year 2025, down from $2,889 million in 2024[32] - Total operating profit for the twelve months ended December 31, 2025, was $3.306 billion, compared to $4.268 billion in 2024, reflecting ongoing challenges[38] Profitability Metrics - Gross profit for Q4 2025 was $3,146 million, with a gross profit margin of 60.2%, slightly down from 60.3% in Q4 2024[30] - Full year gross profit was $12,251 million, with a gross profit margin of 60.1%, down from 60.5% in 2024[32] - Operating profit for Q4 2025 significantly decreased to $92 million, down from $1,064 million in Q4 2024, resulting in an operating profit margin of 1.8% compared to 21.5% in the previous year[30] - The operating profit margin for the three months ended December 31, 2025, was 1.8%, down from 21.5% in 2024, indicating a substantial decline in profitability[52] - Operating profit under GAAP fell by 23% from $4,268 million in 2024 to $3,306 million in 2025[58] - Non-GAAP operating profit remained relatively stable at $4,347 million in 2025 compared to $4,353 million in 2024[58] Shareholder Returns - The company returned $2.9 billion to shareholders through dividends and share repurchases in 2025[4] Future Outlook - The company expects 2026 net sales growth of 2% to 6%, with organic sales growth projected at 1% to 4%[12] - Gross profit margin is expected to expand in 2026, with double-digit earnings per share growth anticipated on a GAAP basis[12] Market Position - Colgate's global market share in toothpaste remained strong at 41.3% year to date[9] Operational Efficiency - Selling, general and administrative expenses as a percentage of net sales increased to 39.6% in 2025 from 38.3% in 2024, indicating rising operational costs[52] - Selling, general and administrative expenses as a percentage of net sales increased from 38.5% in 2024 to 38.8% in 2025[58] Taxation - The effective tax rate for Q4 2025 was 104.7%, a substantial increase from 21.6% in Q4 2024[30] - The effective tax rate for GAAP net income increased from 22.9% in 2024 to 26.1% in 2025[60] Regional Performance - North America sales decreased by 1.5% in the three months ended December 31, 2025, while Latin America saw a significant increase of 12.8%[44] - Sales in Europe increased by 9.8% for the three months ended December 31, 2025, driven by strong pricing strategies[44] Acquisitions and Costs - The acquisition of the Prime100 pet food business contributed 0.5% to the total company volume for the three months ended December 31, 2025[45] - The company reported acquisition-related costs of $9 million in 2025, with no such costs reported in 2024[58] - The restructuring program charges for 2025 were related to the Strategic Growth and Productivity Program and the 2022 Global Productivity Initiative[61] Non-GAAP Metrics - The company reported a non-GAAP net income of $1.038 billion for the three months ended December 31, 2025, a 22.9% increase from $800 million in 2024[54] - Colgate-Palmolive's GAAP gross profit for 2025 was $12,251 million, compared to $12,161 million in 2024, reflecting a slight increase[58] - The gross profit margin under GAAP decreased from 60.5% in 2024 to 60.1% in 2025, a change of -40 basis points[58] - Non-service related postretirement costs under GAAP decreased from $87 million in 2024 to $55 million in 2025[58]

Core Insights - Colgate-Palmolive reported a loss in the fourth quarter due to a significant charge related to its underperforming skin-health business, although sales increased despite challenging market conditions [1] Financial Performance - The company experienced a loss in the fourth quarter, primarily attributed to a large charge associated with its skin-health segment [1] - Sales rose during the quarter, indicating resilience in the face of a difficult operating environment [1]

Core Viewpoint - Colgate-Palmolive forecasts annual sales exceeding Wall Street estimates, driven by consistent demand for essential household products in regions like Latin America and Europe [1] Group 1 - The company is experiencing steady demand for its products, which is contributing to its positive sales outlook [1] - The forecast indicates a strong performance in key markets, particularly in Latin America and Europe [1]

Group 1 - Kongsberg Gruppen, a Norwegian defense company, has secured a significant order worth 16 billion crowns (approximately $1.67 billion) from Poland for drone defense systems [1]

Core Insights - Colgate-Palmolive Company (CL) is anticipated to report revenue growth of 3.3% year-over-year for Q4 2025, with expected revenues of $5.1 billion [1] - The earnings consensus estimate for the quarter is 91 cents per share, remaining flat compared to the previous year [2] Revenue and Earnings Expectations - The Zacks Consensus Estimate for Q4 revenues is $5.1 billion, indicating a 3.3% increase from the prior year's quarter [1] - Earnings per share (EPS) is estimated at 91 cents, unchanged from the previous year, with a slight downward adjustment in the past week [2] Earnings Prediction Model - The current model indicates a negative Earnings ESP of -0.04% and a Zacks Rank of 4 (Sell), suggesting a lower likelihood of an earnings beat this quarter [3] Business Performance Drivers - Colgate's Q4 performance is expected to benefit from strong business momentum, pricing strategies, and productivity initiatives [4] - The company's focus on innovation, premiumization, and digital transformation is projected to enhance its performance [5] Innovation and Product Strategy - Colgate's science-based innovation pipeline, including the relaunch of Colgate Total and advancements in premium oral care, is crucial for category expansion [6] - The company aims to maintain its organic sales trajectory through a resilient portfolio and balanced presence across price tiers [6] Sales Growth Projections - Sales growth for Q4 2025 is predicted at 2.8%, with organic sales growth of 1.4%, offset by a volume decline of 1.3% and pricing gains of 2.7% [7] - Regional sales growth expectations include a 3% rise in Latin America, 9.5% in Europe, and a 6.5% increase in Africa/Eurasia, while North America is expected to see a 0.3% decline [7] Margin and Cost Pressures - Colgate anticipates gross margin compression due to raw material inflation and lower fixed-cost leverage, with a predicted gross margin of 60.2% for Q4 2025 [12][13] - The company is facing challenges from persistent inflation, tariff impacts, and a volatile economic environment, which may constrain near-term earnings growth [11] Long-term Outlook - For 2025, Colgate expects net sales growth in the low single digits, with organic sales growth around 1.2%, despite a drag from exiting private-label pet food [10] - The company remains committed to achieving consistent EPS growth through strong cash flow and ongoing brand investments [10] Market Performance and Valuation - Colgate's shares have increased by 10% over the past three months, outperforming the industry average decline of 3.2% [16] - The stock trades at a forward P/E multiple of 22.21X, higher than the industry average of 18.47X, indicating a relatively pricey valuation compared to peers [17]

Core Viewpoint - Colgate-Palmolive is expected to report flat earnings of $0.91 per share for the quarter ended December 2025, with revenues projected at $5.1 billion, reflecting a 3.2% increase from the previous year [1][3]. Earnings Expectations - The earnings report is scheduled for January 30, and better-than-expected results could lead to a stock price increase, while disappointing results may cause a decline [2]. - The consensus EPS estimate has been revised down by 0.35% over the last 30 days, indicating a bearish sentiment among analysts [4]. Earnings Surprise Prediction - The Most Accurate Estimate for Colgate-Palmolive is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.04%, which complicates predictions of an earnings beat [12]. - The stock currently holds a Zacks Rank of 4, suggesting a less favorable outlook for an earnings surprise [12]. Historical Performance - In the last reported quarter, Colgate-Palmolive exceeded the consensus EPS estimate of $0.89 by delivering earnings of $0.91, resulting in a surprise of +2.25% [13]. - The company has successfully beaten consensus EPS estimates in the last four quarters [14]. Conclusion - Colgate-Palmolive does not appear to be a strong candidate for an earnings beat based on current estimates and rankings, but other factors should also be considered when evaluating the stock ahead of its earnings release [17].

Group 1 - Colgate-Palmolive Company (NYSE:CL) is recognized as one of the 13 Best Dividend Kings to buy in 2026, indicating strong dividend performance potential [1] - Barclays raised its price target for Colgate from $80 to $83 while maintaining an Equal Weight rating, citing a shift towards defensive stocks amid market uncertainty [2] - Wells Fargo upgraded Colgate to Equal Weight from Underweight and increased its price target from $77 to $86, suggesting a more favorable risk/reward profile at current levels [3] Group 2 - Colgate-Palmolive operates in consumer products, focusing on Oral Care, Personal Care, Home Care, and Pet Nutrition categories [4] - Despite the potential of Colgate as an investment, there are suggestions that certain AI stocks may offer greater upside potential with less downside risk [4]

Core Viewpoint - Colgate-Palmolive Company will host a live webcast for its 2025 fourth quarter and full year earnings conference call on January 30, 2026, at 8:30 a.m. ET [1] Company Information - The earnings call will be led by Chairman, President and CEO Noel Wallace, CFO Stan Sutula, and Chief Investor Relations Officer and EVP of M&A John Faucher [1] - Investors can access the earnings press release, prepared materials, and the live audio webcast on Colgate's official website [1]

Core Insights - The Shanghai Municipal Market Supervision Administration conducted a quality inspection of toothpaste products in 2025, with 30 batches tested and no non-compliance found [2]. Group 1: Inspection Results - The inspection was based on the JJF 1070-2023 standards for measuring the net content of packaged goods, focusing on net content labeling and actual net content [2]. - All tested toothpaste products met the relevant standards, indicating a high level of compliance in the market [2]. Group 2: Product Details - Various brands and types of toothpaste were included in the inspection, such as: - DARLIE's mineral toothpaste (120g) from Haolai Chemical [2] - Yunnan Baiyao's sensitive toothpaste (110g) from Yunnan Baiyao Group [2] - Colgate's 3D whitening toothpaste (90g) from Procter & Gamble [2] - The inspection covered products sold in multiple retail locations, including shopping malls and e-commerce platforms [2].

Core Viewpoint - Colgate-Palmolive Company (NYSE:CL) is recognized as a strong investment opportunity within the beauty stock sector, despite challenges in the consumer staples market [1]. Group 1: Analyst Ratings and Price Targets - TD Cowen has reduced Colgate-Palmolive's price target from $90 to $86 while maintaining a Buy rating, anticipating a challenging year for large-cap consumer staples with pricing remaining restrained and volume growth unlikely to improve from the negative 0.9% reported in 2025 [2]. - Piper Sandler upgraded its price target from $82 to $88 and raised Colgate-Palmolive from Neutral to Overweight, noting that shares are already priced for the ongoing Q4 decline and forecasting potential growth in 2026 due to early signs of growth in emerging markets [3]. Group 2: Market Position and Growth Potential - Colgate-Palmolive has established itself as a dominant leader in the household and personal care industries, with a noted lower dependency on the US market due to its involvement in emerging markets, which may enhance its growth prospects [3].